nach oben

Medical Oncology

Erschienen in:

01.09.2009 | Original Paper

The effect of Saccharomyces boulardii on reducing irinotecan-induced intestinal mucositis and diarrhea

verfasst von: Atakan Sezer, Ufuk Usta, Irfan Cicin

Erschienen in: Medical Oncology | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

To investigate the efficiency of Saccharomyces boulardii on irinotecan-induced mucosal damage and diarrhea in rats, fifty rats were randomized into three groups with 20 rats in two study groups and 10 rats in the control group. Control group did not receive any treatment. Irinotecan (60 mg/kg) alone was administered intravenously once a day for four consecutive days to the rats of Group A. Throughout the experiment, Group B rats were additionally given Saccharomyces boulardii (800 mg/kg) for 3 days before administration of irinotecan and 7 days throughout the experiment. Delayed diarrhea was more severe in Group A than Group B (P = 0.009). The weight loss was 34.7 ± 3.8 mg for Group A, while it was 17.4 ± 1.7 mg for Group B (P < 0.001). Findings of mucositis most clearly appeared in the jejunum. Regarding edema (P = 0.003), leukocyte migration (P = 0.038), and inflammation (P = 0.006) significant recovery was detected in the mucosa of rats receiving Saccharomyces boulardii. Villous thickness was significantly greater in Group A than Group B (P < 0.001). The results indicate that Saccharomyces boulardii provided significant improvement in irinotecan-induced diarrhea and mucositis.

Tanizawa A, Fujimori A, Fujimori Y, Pommier Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst (Bethesda). 1994;86:836–42. doi:10.1093/jnci/86.11.836.CrossRef

Douillard JY, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for colorectal cancer: a multicenter randomized trial. Lancet. 2000;355:1041–7. doi:10.1016/S0140-6736(00)02034-1.PubMedCrossRef

Park SH, et al. Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer. Ann Oncol. 2008;19:729–33. doi:10.1093/annonc/mdm502.PubMedCrossRef

Hanna N, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006;24:2038–43. doi:10.1200/JCO.2005.04.8595.PubMedCrossRef

Muggia FM, Blessing JA, McGehee R, Monk BJ. Cisplatin and irinotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2004;94:483–7. doi:10.1016/j.ygyno.2004.05.018.PubMedCrossRef

Ribrag V, et al. Phase II trial of irinotecan (CPT-11) in relapsed or refractory non-Hodgkin’s lymphomas. Leuk Lymphoma. 2003;44:1529–33. doi:10.1080/1042819031000099643.PubMedCrossRef

Stringer AM, et al. Chemotherapy-induced mucositis: the role of gastrointestinal microflora and mucins in the luminal environment. J Support Oncol. 2007;5:259–67.PubMed

Gibson RJ, Bowen JM, Inglis MR, Cummins AG, Keefe DM. Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol. 2003;18:1095–100. doi:10.1046/j.1440-1746.2003.03136.x.PubMedCrossRef

Buts JP. Twenty-five years of research on Saccharomyces boulardii trophic effects: updates and perspectives. Dig Dis Sci. 2008 (in press).

10.

Surawicz CM, et al. Prevention of antibiotic associated diarrhoea by Saccharomyces boulardii: a prospective study. Gastroenterology. 1989;96:981–8.PubMed

11.

McFarland LV, et al. Prevention of ß–lactam associated diarrhoea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol. 1995;90:439–48.PubMed

12.

McFarland LV, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 1994;271:1913–8. doi:10.1001/jama.271.24.1913.PubMedCrossRef

13.

Surawicz CM, et al. The search for a better treatment for Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis. 2000;31:1012–7. doi:10.1086/318130.PubMedCrossRef

14.

Buts JP, Corthier G, Delm’ee M. Saccharomyces boulardii for Clostridium difficile-associated enterocolopathies in infants. J Pediatr Gastroenterol Nutr. 1993;16:1497–504. doi:10.1097/00005176-199305000-00013.

15.

Höchter W, Chase D, Hegenhoff G. Saccharomyces boulardii in treatment of acute adult diarrhoea efficacy and tolerance of treatment. Münch Med Wochenschr. 1990;132:188–92.

16.

Kollaritsch H, Holst H, Grobara P, Wiedermann G. Prevention of traveler’s diarrhea with Saccharomyces boulardii. Results of a placebo controlled double-blind study. Forstchr Med. 1993;111:152–6.

17.

Bleichner G, Bléhaut H, Mentec H, Moyse D. Sacchromyces boulardii prevents diarrhoea in critically ill tube-fed patients. A multicenter, randomized, double-blind-placebo-controlled trial. Intensive Care Med. 1997;23:517–23. doi:10.1007/s001340050367.PubMedCrossRef

18.

Saint-Marc T, Bl’ehaut H, Musial C, Touraine JL. Efficacit’e de Saccharomyces boulardii dans le traitement des diarrh’ees du SIDA. Am Med Int. 1991;142:64–5.

19.

Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Dig Dis Sci. 2000;45:1462–4. doi:10.1023/A:1005588911207.PubMedCrossRef

20.

Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol. 2003;15:697–8. doi:10.1097/00042737-200306000-00017.PubMedCrossRef

21.

Pothoulakis C, et al. Saccharomyces boulardii inhibits Clostridium difficile toxin. A binding and enterotoxicity in rat ileum. Gastroenterology. 1993;104:1108–15.PubMed

22.

Czerucka D, Roux I, Rampal P. Saccharomyces boulardii inhibits secretagogue-mediated adenosine 3′,5′-cyclic monophosphate induction in intestinal cells. Gastroenterology. 1994;106:65–72.PubMed

23.

Czerucka D, Rampal P. Effect of Saccharomyces boulardii on cAMP- and Ca2+-dependent Cl-secretion in T84 cells. Dig Dis Sci. 1994;44:2359–68. doi:10.1023/A:1026689628136.CrossRef

24.

Czerucka D, Dahan S, Mograbi B, Rossi B, Rampal P. Saccharomyces boulardii preserves the barrier function and modulates the transduction pathway induced in enteropathogenic Escherichia coli infected T84 cells. Infect Immun. 2000;68:5998–6004. doi:10.1128/IAI.68.10.5998-6004.2000.PubMedCrossRef

25.

Dahan S, et al. Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli induced signalling pathways in T84 cells. Infect Immun. 2003;71:766–73. doi:10.1128/IAI.71.2.766-773.2003.PubMedCrossRef

26.

Dalmasso G, et al. Saccharomyces boulardii prevents TNFa-induced apoptosis in EHEC-infected T84 cells. Res Microbiol. 2006;157:456–66. doi:10.1016/j.resmic.2005.11.007.PubMedCrossRef

27.

Qamar A, et al. Saccharomyces boulardii stimulates intestinal immunoglobulin. A immune response to Clostridium difficile toxin A in mice. Infect Immun. 2001;69:2762–5. doi:10.1128/IAI.69.4.2762-2765.2001.PubMedCrossRef

28.

Powrie F, Leach MW, Mauze S, Caddle LB, Coffman RL. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in CB-17 scid mice. Int Immunol. 1993;5:1461–71. doi:10.1093/intimm/5.11.1461.PubMedCrossRef

29.

Lee SK, Kim YW, Chi SG, Joo YS, Kim HJ. The effect of Saccharomyces boulardii on human colon cells and inflammation in rats with trinitrobenzene sulfonic acid-induced colitis. Dig Dis Sci. 2008 (in press).

30.

Sougioultzis S, et al. Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-κB-mediated IL-8 gene expression. Biochem Biophys Res Commun. 2006;34:69–76. doi:10.1016/j.bbrc.2006.02.080.CrossRef

31.

Buts JP, De Keyser N. Effects of Saccharomyces boulardii on intestinal mucosa. Dig Dis Sci. 2006;51:1485–92. doi:10.1007/s10620-005-9016-x.PubMedCrossRef

32.

Takasuna K, et al. Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea. Cancer Chemother Pharmacol. 2006;58:494–503. doi:10.1007/s00280-006-0187-8.PubMedCrossRef

33.

Logan RM, et al. Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol. 2008;62:33–41. doi:10.1007/s00280-007-0570-0.PubMedCrossRef

34.

Gibson RJ, Keefe DM. Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. Support Care Cancer. 2006;14:890–900. doi:10.1007/s00520-006-0040-y.PubMedCrossRef

35.

Takasuna K, et al. Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res. 1996;56:3752–7.PubMed

36.

Kehrer DF, et al. Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res. 2001;7:1136–41.PubMed

37.

Dalmasso G, et al. Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology. 2006;131:1812–25. doi:10.1053/j.gastro.2006.10.001.PubMedCrossRef

38.

Buts JP, Bernasconi P, Van Craynest MP, Maldague P, De Meyer R. Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii. Pediatr Res. 1986;20:192–6. doi:10.1203/00006450-198602000-00020.PubMedCrossRef

39.

Jahn HU, et al. Immunological and trophical effects of Saccharomyces boulardii on the small intestine in healthy human volunteers. Digestion. 1996;57:95–104.PubMedCrossRef

40.

Harms HK, Bertele-Harms RM, Bruer-Kleis D. Enzyme substitution therapy with the yeast Saccharomyces cerevisiae in congenital sucrase isomaltase deficiency. N Engl J Med. 1987;316:1306–9.PubMed

41.

Buts JP, De Keyser N, Stilmant C, Sokal E, Marandi S. Saccharomyces boulardii enhances N-terminal peptide hydrolysis in suckling rat small intestine by endoluminal release of a zinc binding metalloprotease. Pediatr Res. 2002;51:528–34. doi:10.1203/00006450-200204000-00021.PubMedCrossRef

42.

Buts JP, et al. Saccharomyces boulardii upgrades cellular adaptation after proximal enterectomy in rats. Gut. 1999;45:89–96.PubMedCrossRef

43.

Baum B, Liebler-Tenorio EM, Enss ML, Pohlenz JF, Breves G. Saccharomyces boulardii and Bacillus cereus var. Toyoi influence the morphology and the mucins of the intestine of pigs. Z Gastroenterol. 2002;40:277–84. doi:10.1055/s-2002-30116.PubMedCrossRef

44.

De Preter V, et al. Effect of dietary intervention with different pre- and pro-biotics on intestinal bacterial enzyme activities. Eur J Clin Nutr. 2008;62:225–31. doi:10.1038/sj.ejcn.1602706.PubMedCrossRef

Titel: The effect of Saccharomyces boulardii on reducing irinotecan-induced intestinal mucositis and diarrhea
verfasst von: Atakan Sezer
Ufuk Usta
Irfan Cicin
Publikationsdatum: 01.09.2009
Verlag: Humana Press Inc
Erschienen in: Medical Oncology / Ausgabe 3/2009
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-008-9128-1

Springer Medizin

The effect of Saccharomyces boulardii on reducing irinotecan-induced intestinal mucositis and diarrhea

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2009

A phase I clinical study of intratumorally administered VB4-845, an anti-epithelial cell adhesion molecule recombinant fusion protein, in patients with squamous cell carcinoma of the head and neck

Real-time quantitative RT-PCR assessment of PIM-1 and hK2 mRNA expression in benign prostate hyperplasia and prostate cancer

Endoscopic mucosa resection of a duodenum carcinoid tumor of 1.2 cm diameter: a case report

Evaluation of galectin-8 expression in thyroid tumors

PIK3CA mutation occurs in nasopharyngeal carcinoma but does not significantly influence the disease-specific survival

Laboratory investigation of hypercoagulability in cancer patients using rotation thrombelastography

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie